• Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech


192.0000 DKK 9.0000 4.92%

As of 11:03:05 ET on 04/16/2014.

Snapshot for Genmab A/S (GEN)

Open: 188.1000 Day's Range: 185.5000 - 192.7000 Volume: 542,546
Previous Close: 183.0000 52wk Range: 130.0000 - 260.0000 1-Yr Rtn: +30.26%

Stock Chart for GEN

No chart data available.
  • GEN:DC 192.0000
  • 1D
  • 1M
  • 1Y
Interactive GEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GEN

Current P/E Ratio (ttm) 136.7176
Estimated P/E(12/2014) 69.6157
Relative P/E vs. KFX 6.2241
Earnings Per Share (DKK) (ttm) 1.4044
Est. EPS (DKK) (12/2014) 2.7580
Est. PEG Ratio -
Market Cap (M DKK) 10,872.81
Shares Outstanding (M) 56.63
30 Day Average Volume 312,954
Price/Book (mrq) 15.0671
Price/Sale (ttm) 14.7318
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GEN

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GEN

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Links
sec ||= nil